Global Blood Therapeutics Stock Price, News & Analysis (NASDAQ:GBT)

$44.77 -0.93 (-2.04 %)
(As of 12/11/2017 04:00 PM ET)
Previous Close$45.70
Today's Range$38.05 - $45.85
52-Week Range$13.35 - $45.85
Volume4.09 million shs
Average Volume1.00 million shs
Market Capitalization$1.96 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics logoGlobal Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:GBT
CUSIPN/A
Phone+1-650-7417700

Debt

Debt-to-Equity RatioN/A
Current Ratio14.05%
Quick Ratio14.05%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.99 per share
Price / Book8.97

Profitability

Trailing EPS($2.55)
Net Income$-82,460,000.00
Net MarginsN/A
Return on Equity-40.04%
Return on Assets-37.24%

Miscellaneous

Employees95
Outstanding Shares43,700,000

Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.66) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.04. During the same period last year, the firm earned ($0.58) EPS. View Global Blood Therapeutics' Earnings History.

Where is Global Blood Therapeutics' stock going? Where will Global Blood Therapeutics' stock price be in 2017?

13 brokers have issued twelve-month price objectives for Global Blood Therapeutics' stock. Their forecasts range from $37.00 to $91.00. On average, they expect Global Blood Therapeutics' stock price to reach $60.62 in the next twelve months. View Analyst Ratings for Global Blood Therapeutics.

What are Wall Street analysts saying about Global Blood Therapeutics stock?

Here are some recent quotes from research analysts about Global Blood Therapeutics stock:

  • 1. Cantor Fitzgerald analysts commented, "At ASH, Global Blood announced multi-dose Phase 2a data with voxelotor (GBT440), in adolescent (ages 12-17) patients." (12/11/2017)
  • 2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (12/6/2017)
  • 3. Cowen Inc analysts commented, "GBT reported Q3 earnings last week and provided a brief summary of their progress." (11/9/2017)
  • 4. Wedbush analysts commented, "Global Blood Therapeutics (GBT) is developing GBT440 to reduce the severity and frequency of crises and pain associated with sickle cell disease (SCD) and to improve blood oxygenation characteristics and quality of life for IPF. In 2017, we see release of Phase 2a GBT440 testing in IPF as the most material catalyst unless GBT is acquired. We calculate that the recent uptick following acquisition speculation is too low."We believe GBT440's emerging clinical profile suggests potential for disease modification and becoming the foundation treatment for SCD. To date the emerging clinical profile includes a convenient once daily oral dosing; being safe and well tolerated and recent longer-term dosing suggests durability of effect and in our view partially de-risks Phase 3. Investor concerns include lack of dose response, new PRO and competition." (3/20/2017)
  • 5. J P Morgan Chase & Co analysts commented, "This evening GBT released 4Q results via press release (no conference call, as usual). The update was largely review and in-line with recent commentary; see our takeaways from the J.P. Morgan Healthcare Conference here. More significant than tonight’s print was Reuter’s report last week (here) that Novo Nordisk may have interest in GBT, and a subsequent Reuter’s story (here) that quoted NVO’s CEO saying “In my view we should do smaller deals; low single-digit billions of dollars.” On this front, we do believe that GBT could be a strong strategic fit for companies currently involved in the non-oncology hematology space. More broadly, we continue to think GBT440 is a promising wholly owned asset targeting a large and underserved market with the potential for initial IPF data later this year and a key sickle cell update currently anticipated in 2018." (3/15/2017)

Who are some of Global Blood Therapeutics' key competitors?

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the folowing people:

  • Ted W. Love M.D., President, Chief Executive Officer, Director (Age 58)
  • Jeffrey S. Farrow, Chief Financial Officer (Age 55)
  • Peter Radovich, Senior Vice President, Operations (Age 39)
  • Hing L. Sham, Senior Vice President, Research (Age 64)
  • Jung E. Choi, Chief Business and Strategy Officer (Age 47)
  • Tricia Borga Suvari Esq., Chief Legal Officer (Age 56)
  • Charles J. Homcy M.D., Director (Age 68)
  • Willie L. Brown Jr, Independent Director (Age 83)
  • Scott W. Morrison, Independent Director (Age 59)
  • Deval L. Patrick, Independent Director (Age 60)

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Who owns Global Blood Therapeutics stock?

Global Blood Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (9.76%), Orbimed Advisors LLC (5.48%), Point72 Asset Management L.P. (4.63%), Janus Henderson Group PLC (3.24%), Sectoral Asset Management Inc (1.22%) and Fernwood Investment Management LLC (0.96%). Company insiders that own Global Blood Therapeutics stock include Charles J Homcy, Deval L Patrick, Eleanor Ramos, John Schembri, Jung Choi, Kevin P Starr, Peter Radovich and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics.

Who sold Global Blood Therapeutics stock? Who is selling Global Blood Therapeutics stock?

Global Blood Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Iguana Healthcare Management LLC, OxFORD Asset Management LLP, Wells Fargo & Company MN, Marcus Capital LLC, Sphera Funds Management LTD., EAM Investors LLC, California State Teachers Retirement System and Cubist Systematic Strategies LLC. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Charles J Homcy, Deval L Patrick, Jung Choi, Kevin P Starr, Peter Radovich and Robert I Tepper. View Insider Buying and Selling for Global Blood Therapeutics.

Who bought Global Blood Therapeutics stock? Who is buying Global Blood Therapeutics stock?

Global Blood Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Janus Henderson Group PLC, Perceptive Advisors LLC, NF Trinity Capital Hong Kong Ltd, Orbimed Advisors LLC, Fernwood Investment Management LLC, Sectoral Asset Management Inc and Cornerstone Capital Management Holdings LLC.. Company insiders that have bought Global Blood Therapeutics stock in the last two years include Eleanor Ramos and John Schembri. View Insider Buying and Selling for Global Blood Therapeutics.

How do I buy Global Blood Therapeutics stock?

Shares of Global Blood Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of Global Blood Therapeutics stock can currently be purchased for approximately $44.77.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $1.96 billion. The company earns $-82,460,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Global Blood Therapeutics employs 95 workers across the globe.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 400 E Jamie Ct Ste 101, SOUTH SAN FRANCISCO, CA 94080-6230, United States. The company can be reached via phone at +1-650-7417700 or via email at [email protected]


MarketBeat Community Rating for Global Blood Therapeutics (GBT)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  323
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Global Blood Therapeutics (NASDAQ:GBT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $57.93$53.92$53.73$51.10
Price Target Upside: 26.77% upside40.24% upside83.39% upside66.16% upside

Global Blood Therapeutics (NASDAQ:GBT) Consensus Price Target History

Price Target History for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ:GBT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017NomuraBoost Price TargetBuy$91.00HighView Rating Details
12/11/2017HC WainwrightSet Price TargetBuy$73.00HighView Rating Details
12/11/2017Cantor FitzgeraldSet Price TargetBuy$61.00HighView Rating Details
12/4/2017WedbushReiterated RatingOutperform$73.00HighView Rating Details
11/13/2017OppenheimerSet Price TargetBuy$53.00N/AView Rating Details
11/9/2017CowenReiterated RatingBuy$83.00N/AView Rating Details
11/6/2017SunTrust BanksBoost Price TargetBuy$67.00N/AView Rating Details
10/23/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
10/24/2017Needham & Company LLCSet Price TargetBuy$51.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$51.00 -> $56.00N/AView Rating Details
5/1/2017Janney Montgomery ScottInitiated CoverageBuy$37.00LowView Rating Details
3/20/2017Roth CapitalSet Price TargetBuy$47.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$50.00N/AView Rating Details
9/30/2016Wells Fargo & CompanyInitiated CoverageOutperform$75.00 -> $23.05N/AView Rating Details
2/22/2016Goldman Sachs GroupLower Price Target$43.00 -> $26.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Global Blood Therapeutics (NASDAQ:GBT) Earnings History and Estimates Chart

Earnings by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ GBT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.62)($0.66)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.61)($0.55)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.71)($0.60)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.64)($0.74)ViewN/AView Earnings Details
11/9/2016Q316($0.58)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.63)($0.58)ViewN/AView Earnings Details
5/12/2016Q1($0.48)($0.56)ViewN/AView Earnings Details
3/29/2016Q4($0.64)($0.53)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.71)($0.90)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Global Blood Therapeutics (NASDAQ:GBT) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20171($0.69)($0.69)($0.69)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Global Blood Therapeutics (NASDAQ:GBT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Global Blood Therapeutics (NASDAQ GBT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 90.48%
Insider Trades by Quarter for Global Blood Therapeutics (NASDAQ:GBT)
Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ GBT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/30/2017Peter RadovichVPSell12,500$35.00$437,500.00View SEC Filing  
10/27/2017Charles J HomcyDirectorSell70,000$33.97$2,377,900.00View SEC Filing  
10/17/2017Jung ChoiInsiderSell3,000$32.65$97,950.00View SEC Filing  
9/29/2017Jung ChoiInsiderSell3,000$30.00$90,000.00View SEC Filing  
8/31/2017Jung ChoiInsiderSell3,000$30.00$90,000.00View SEC Filing  
7/25/2017Deval L PatrickDirectorSell27,053$29.69$803,203.57View SEC Filing  
7/21/2017Jung ChoiInsiderSell3,000$30.00$90,000.00View SEC Filing  
4/6/2017Robert I TepperMajor ShareholderSell31,225$33.23$1,037,606.75View SEC Filing  
12/16/2016Kevin P StarrMajor ShareholderSell108,955$16.00$1,743,280.00View SEC Filing  
1/7/2016John SchembriinsiderBuy1,500$21.57$32,355.00View SEC Filing  
12/22/2015Eleanor RamosinsiderBuy11,000$20.93$230,230.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Global Blood Therapeutics (NASDAQ GBT) News Headlines

Source:
DateHeadline
Global Blood Therapeutics (GBT) Price Target Increased to $91.00 by Analysts at NomuraGlobal Blood Therapeutics (GBT) Price Target Increased to $91.00 by Analysts at Nomura
www.americanbankingnews.com - December 11 at 5:46 PM
11 Biotech Stocks Moving From ASH 2017 - Benzinga11 Biotech Stocks Moving From ASH 2017 - Benzinga
www.benzinga.com - December 11 at 5:18 PM
Morgan Stanley: Global Blood Therapeutics Clearly Encouraged By Sickle Cell Therapy Data - BenzingaMorgan Stanley: Global Blood Therapeutics 'Clearly Encouraged' By Sickle Cell Therapy Data - Benzinga
www.benzinga.com - December 11 at 5:18 PM
Global Blood Therapeutics (GBT) Announces Presentation of Six Studies at ASH Supporting Voxelotor SCD Program - StreetInsider.comGlobal Blood Therapeutics (GBT) Announces Presentation of Six Studies at ASH Supporting Voxelotor SCD Program - StreetInsider.com
www.streetinsider.com - December 11 at 5:18 PM
HC Wainwright Reiterates "$73.00" Price Target for Global Blood Therapeutics (GBT)HC Wainwright Reiterates "$73.00" Price Target for Global Blood Therapeutics (GBT)
www.americanbankingnews.com - December 11 at 9:52 AM
Global Blood Therapeutics: Hopeful Uncertainty - Seeking Alpha - Seeking AlphaGlobal Blood Therapeutics: Hopeful Uncertainty - Seeking Alpha - Seeking Alpha
seekingalpha.com - December 8 at 5:01 PM
Global Blood Therapeutics (GBT) Upgraded at Zacks Investment ResearchGlobal Blood Therapeutics (GBT) Upgraded at Zacks Investment Research
www.americanbankingnews.com - December 6 at 9:58 PM
Global Blood Therapeutics, Inc. (GBT) Forecasted to Post FY2018 Earnings of ($3.30) Per ShareGlobal Blood Therapeutics, Inc. (GBT) Forecasted to Post FY2018 Earnings of ($3.30) Per Share
www.americanbankingnews.com - December 6 at 3:08 PM
Global Blood Therapeutics, Inc. (GBT) to Post FY2017 Earnings of ($2.51) Per Share, Wedbush ForecastsGlobal Blood Therapeutics, Inc. (GBT) to Post FY2017 Earnings of ($2.51) Per Share, Wedbush Forecasts
www.americanbankingnews.com - December 6 at 6:50 AM
Wedbush Reaffirms Outperform Rating for Global Blood Therapeutics (GBT)Wedbush Reaffirms Outperform Rating for Global Blood Therapeutics (GBT)
www.americanbankingnews.com - December 4 at 8:06 AM
ValuEngine Downgrades Global Blood Therapeutics (GBT) to SellValuEngine Downgrades Global Blood Therapeutics (GBT) to Sell
www.americanbankingnews.com - December 3 at 12:44 PM
25 Stocks Moving In Fridays Mid-Day Session - Benzinga25 Stocks Moving In Friday's Mid-Day Session - Benzinga
www.benzinga.com - December 1 at 5:05 PM
This Mornings Research Reports on Biotechnology Stocks -- FibroGen, Global Blood Therapeutics, Intercept Pharma ... - PR Newswire (press release)This Morning's Research Reports on Biotechnology Stocks -- FibroGen, Global Blood Therapeutics, Intercept Pharma ... - PR Newswire (press release)
www.prnewswire.com - December 1 at 5:05 PM
Benzingas Top Upgrades, Downgrades For December 1, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For December 1, 2017 - Benzinga
www.benzinga.com - December 1 at 5:05 PM
Global Blood Therapeutics Announces New Employment ... - GlobeNewswire (press release)Global Blood Therapeutics Announces New Employment ... - GlobeNewswire (press release)
globenewswire.com - December 1 at 5:05 PM
Global Blood Therapeutics (GBT) Research Coverage Started at HC WainwrightGlobal Blood Therapeutics (GBT) Research Coverage Started at HC Wainwright
www.americanbankingnews.com - December 1 at 7:49 AM
Global Blood Therapeutics, Inc. Fundamental Analysis : November 30, 2017Global Blood Therapeutics, Inc. Fundamental Analysis : November 30, 2017
finance.yahoo.com - November 30 at 5:03 PM
Global Blood Therapeutics, Inc. (GBT) Given Consensus Rating of "Buy" by BrokeragesGlobal Blood Therapeutics, Inc. (GBT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 23 at 10:06 PM
An Integrated Research On Global Blood Therapeutics: Is Voxelotor The Answer For Sickle Cell Disease? - Seeking AlphaAn Integrated Research On Global Blood Therapeutics: Is Voxelotor The Answer For Sickle Cell Disease? - Seeking Alpha
seekingalpha.com - November 19 at 4:15 AM
Global Blood Therapeutics (GBT) versus Oramed Pharmaceuticals (ORMP) Head to Head ContrastGlobal Blood Therapeutics (GBT) versus Oramed Pharmaceuticals (ORMP) Head to Head Contrast
www.americanbankingnews.com - November 16 at 5:20 AM
Global Blood Therapeutics, Inc. (GBT) Given a $53.00 Price Target at Oppenheimer Holdings, Inc.Global Blood Therapeutics, Inc. (GBT) Given a $53.00 Price Target at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 13 at 4:31 PM
Global Blood Therapeutics (GBT) Announces Completion of Safety Review by Independent DSMB for Phase 3 HOPE ... - StreetInsider.comGlobal Blood Therapeutics (GBT) Announces Completion of Safety Review by Independent DSMB for Phase 3 HOPE ... - StreetInsider.com
www.streetinsider.com - November 13 at 9:46 AM
Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell DiseaseGlobal Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease
finance.yahoo.com - November 13 at 9:46 AM
Global Blood Therapeutics, Inc. (GBT) Given Buy Rating at Cowen and CompanyGlobal Blood Therapeutics, Inc. (GBT) Given Buy Rating at Cowen and Company
www.americanbankingnews.com - November 9 at 3:42 PM
January 2018 Options Now Available For Global Blood Therapeutics (GBT) - NasdaqJanuary 2018 Options Now Available For Global Blood Therapeutics (GBT) - Nasdaq
www.nasdaq.com - November 7 at 12:43 AM
Global Blood Therapeutics, Inc. (GBT) Given New $67.00 Price Target at SunTrust Banks, Inc.Global Blood Therapeutics, Inc. (GBT) Given New $67.00 Price Target at SunTrust Banks, Inc.
www.americanbankingnews.com - November 6 at 11:39 AM
Global Blood Therapeutics, Inc. (GBT) Expected to Announce Earnings of -$0.67 Per ShareGlobal Blood Therapeutics, Inc. (GBT) Expected to Announce Earnings of -$0.67 Per Share
www.americanbankingnews.com - November 5 at 11:44 AM
Global Blood Therapeutics, Inc. (GBT) Announces Quarterly  Earnings ResultsGlobal Blood Therapeutics, Inc. (GBT) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 3 at 9:30 PM
Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial ResultsGlobal Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results
www.thestreet.com - November 3 at 12:04 PM
Global Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th ... - GlobeNewswire (press release)Global Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th ... - GlobeNewswire (press release)
globenewswire.com - November 2 at 8:12 PM
Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial ResultsGlobal Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 8:12 PM
Global Blood reports 3Q lossGlobal Blood reports 3Q loss
finance.yahoo.com - November 2 at 8:12 PM
Global Blood Therapeutics - The Halloween 2017 Bioscience StockGlobal Blood Therapeutics - The Halloween 2017 Bioscience Stock
seekingalpha.com - November 1 at 8:13 PM
Global Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th American Society of Hematology (ASH) Annual MeetingGlobal Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 1 at 8:13 PM
Global Blood Therapeutics, Inc. (GBT) VP Peter Radovich Sells 12,500 SharesGlobal Blood Therapeutics, Inc. (GBT) VP Peter Radovich Sells 12,500 Shares
www.americanbankingnews.com - October 31 at 11:28 PM
Global Blood Therapeutics, Inc. (GBT) to Release Earnings on TuesdayGlobal Blood Therapeutics, Inc. (GBT) to Release Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:34 AM
Bioscience Catalysts: Global Blood Therapeutics And Vanda PharmaceuticalsBioscience Catalysts: Global Blood Therapeutics And Vanda Pharmaceuticals
seekingalpha.com - October 31 at 5:54 AM
Global Blood Therapeutics: When Single-Patient Data Is A Significant CatalystGlobal Blood Therapeutics: When Single-Patient Data Is A Significant Catalyst
seekingalpha.com - October 30 at 7:51 PM
Global Blood Therapeutics Inc. Jumped as Much as 14% on This NewsGlobal Blood Therapeutics Inc. Jumped as Much as 14% on This News
finance.yahoo.com - October 30 at 7:51 PM
Global Blood Therapeutics Announces Presentation...Global Blood Therapeutics Announces Presentation...
www.benzinga.com - October 30 at 4:07 AM
Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440 ... - GlobeNewswire (press release)Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440 ... - GlobeNewswire (press release)
globenewswire.com - October 29 at 12:22 AM
Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient with Severe and Symptomatic AnemiaGlobal Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient with Severe and Symptomatic Anemia
finance.yahoo.com - October 28 at 7:21 PM
Charles J. Homcy Sells 70,000 Shares of Global Blood Therapeutics, Inc. (GBT) StockCharles J. Homcy Sells 70,000 Shares of Global Blood Therapeutics, Inc. (GBT) Stock
www.americanbankingnews.com - October 27 at 8:22 PM
Global Blood Therapeutics: Addressing A Sickle That Impedes Critical CyclingGlobal Blood Therapeutics: Addressing A Sickle That Impedes Critical Cycling
seekingalpha.com - October 26 at 8:23 PM
Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440 - GlobeNewswire (press release)Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440 - GlobeNewswire (press release)
globenewswire.com - October 25 at 6:07 AM
Global Blood To Discontinue GBT 440 Program For Idiopathic Pulmonary FibrosisGlobal Blood To Discontinue GBT 440 Program For Idiopathic Pulmonary Fibrosis
www.rttnews.com - October 25 at 12:46 AM
BRIEF-Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440BRIEF-Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440
www.reuters.com - October 25 at 12:46 AM
Global Blood Therapeutics (GBT) to Discontinue GBT440 Program for Treatment of IPFGlobal Blood Therapeutics (GBT) to Discontinue GBT440 Program for Treatment of IPF
www.streetinsider.com - October 25 at 12:46 AM
Global Blood Therapeutics stock drops 11.5% after discontinuation of pulmonary fibrosis therapyGlobal Blood Therapeutics stock drops 11.5% after discontinuation of pulmonary fibrosis therapy
finance.yahoo.com - October 25 at 12:46 AM
Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440
finance.yahoo.com - October 25 at 12:46 AM

SEC Filings

Global Blood Therapeutics (NASDAQ:GBT) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Global Blood Therapeutics (NASDAQ:GBT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Global Blood Therapeutics (NASDAQ GBT) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.